Cargando…
Pharmacological and Nonpharmacological Treatments for Painful Diabetic Peripheral Neuropathy
Diabetic peripheral neuropathy (DPN) is one of the most prevalent chronic complications of diabetes. The lifetime prevalence of DPN is thought to be >50%, and 15%–25% of patients with diabetes experience neuropathic pain, referred to as “painful DPN.” Appropriate treatment of painful DPN is impor...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Diabetes Association
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10695723/ https://www.ncbi.nlm.nih.gov/pubmed/37670573 http://dx.doi.org/10.4093/dmj.2023.0018 |
_version_ | 1785153624602574848 |
---|---|
author | Jang, Han Na Oh, Tae Jung |
author_facet | Jang, Han Na Oh, Tae Jung |
author_sort | Jang, Han Na |
collection | PubMed |
description | Diabetic peripheral neuropathy (DPN) is one of the most prevalent chronic complications of diabetes. The lifetime prevalence of DPN is thought to be >50%, and 15%–25% of patients with diabetes experience neuropathic pain, referred to as “painful DPN.” Appropriate treatment of painful DPN is important because this pain contributes to a poor quality of life by causing sleep disturbance, anxiety, and depression. The basic principle for the management of painful DPN is to control hyperglycemia and other modifiable risk factors, but these may be insufficient for preventing or improving DPN. Because there is no promising diseasemodifying medication for DPN, the pain itself needs to be managed when treating painful DPN. Drugs for neuropathic pain, such as gabapentinoids, serotonin–norepinephrine reuptake inhibitors, tricyclic antidepressants, alpha-lipoic acid, sodium channel blockers, and topical capsaicin, are used for the management of painful DPN. The U.S. Food and Drug Administration (FDA) has approved pregabalin, duloxetine, tapentadol, and the 8% capsaicin patch as drugs for the treatment of painful DPN. Recently, spinal cord stimulation using electrical stimulation is approved by the FDA for the treatment for painful DPN. This review describes the currently available pharmacological and nonpharmacological treatments for painful DPN. |
format | Online Article Text |
id | pubmed-10695723 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Korean Diabetes Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-106957232023-12-05 Pharmacological and Nonpharmacological Treatments for Painful Diabetic Peripheral Neuropathy Jang, Han Na Oh, Tae Jung Diabetes Metab J Review Diabetic peripheral neuropathy (DPN) is one of the most prevalent chronic complications of diabetes. The lifetime prevalence of DPN is thought to be >50%, and 15%–25% of patients with diabetes experience neuropathic pain, referred to as “painful DPN.” Appropriate treatment of painful DPN is important because this pain contributes to a poor quality of life by causing sleep disturbance, anxiety, and depression. The basic principle for the management of painful DPN is to control hyperglycemia and other modifiable risk factors, but these may be insufficient for preventing or improving DPN. Because there is no promising diseasemodifying medication for DPN, the pain itself needs to be managed when treating painful DPN. Drugs for neuropathic pain, such as gabapentinoids, serotonin–norepinephrine reuptake inhibitors, tricyclic antidepressants, alpha-lipoic acid, sodium channel blockers, and topical capsaicin, are used for the management of painful DPN. The U.S. Food and Drug Administration (FDA) has approved pregabalin, duloxetine, tapentadol, and the 8% capsaicin patch as drugs for the treatment of painful DPN. Recently, spinal cord stimulation using electrical stimulation is approved by the FDA for the treatment for painful DPN. This review describes the currently available pharmacological and nonpharmacological treatments for painful DPN. Korean Diabetes Association 2023-11 2023-09-06 /pmc/articles/PMC10695723/ /pubmed/37670573 http://dx.doi.org/10.4093/dmj.2023.0018 Text en Copyright © 2023 Korean Diabetes Association https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Jang, Han Na Oh, Tae Jung Pharmacological and Nonpharmacological Treatments for Painful Diabetic Peripheral Neuropathy |
title | Pharmacological and Nonpharmacological Treatments for Painful Diabetic Peripheral Neuropathy |
title_full | Pharmacological and Nonpharmacological Treatments for Painful Diabetic Peripheral Neuropathy |
title_fullStr | Pharmacological and Nonpharmacological Treatments for Painful Diabetic Peripheral Neuropathy |
title_full_unstemmed | Pharmacological and Nonpharmacological Treatments for Painful Diabetic Peripheral Neuropathy |
title_short | Pharmacological and Nonpharmacological Treatments for Painful Diabetic Peripheral Neuropathy |
title_sort | pharmacological and nonpharmacological treatments for painful diabetic peripheral neuropathy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10695723/ https://www.ncbi.nlm.nih.gov/pubmed/37670573 http://dx.doi.org/10.4093/dmj.2023.0018 |
work_keys_str_mv | AT janghanna pharmacologicalandnonpharmacologicaltreatmentsforpainfuldiabeticperipheralneuropathy AT ohtaejung pharmacologicalandnonpharmacologicaltreatmentsforpainfuldiabeticperipheralneuropathy |